Cancer Foundation Finland Grant Call 2026: Historical Record of Major, Research and Dissertation Grants
Historical reference for Cancer Foundation Finland’s 2026 annual cancer-research grant call, which closed on 19 August 2026. It offered three €600,000 major grants, one-to-three-year research grants, and €4,000 dissertation grants. The foundation has not announced a subsequent call on its official call page.
Cancer Foundation Finland Grant Call 2026: Historical Record of Major, Research and Dissertation Grants
Status of this opportunity
The Cancer Foundation Finland’s 2026 summer call is closed. The published application period ended on 19 August 2026 at 23:59, and the foundation states that late applications are rejected and that submitted applications cannot be supplemented after the closing time. The official call page continues to describe the 2026 round. It does not publish a later call or a new application deadline, so this page is a historical reference, not an invitation to apply. Do not send an application through the old form expecting the foundation to accept it for the closed round. The next call’s dates and terms should be taken from a new official announcement when the foundation publishes one.
The foundation’s current call pages say that awards from this round will be announced in December 2026. That announcement concerns the applications already submitted; it does not reopen the call. The published research and major grant guidance says the first instalment is expected in January 2027, after award and payment details have been provided through the application system. Those prospective dates belong to administration of the 2026 awards and should not be read as application dates.
What the 2026 call offered
Cancer Foundation Finland invited applications for cancer research carried out in Finland. Its call covered biological, clinical, epidemiological and psychosocial research, including basic cancer research. The foundation described the major awards as non-targeted: applicants proposed cancer research of their own choosing, and reviewers assessed the proposal’s scientific quality, feasibility, the applicant’s merits and its relevance to cancer. The topic did not need to match a narrow annual theme, but the connection to cancer or cancer prevention, detection, treatment or rehabilitation had to be clear in the application.
The largest awards were three major grants of €600,000 each for three years. These were intended for senior-level researchers and substantial research programmes. The amount and duration were set for the 2026 call; they should not be assumed for a future round. Applicants who were not selected for a major grant could have their applications considered together with applications for other research grants, according to the official major-grant guidance.
The research-grant category offered support for one, two or three years. The foundation said it would prioritise longer periods, while retaining the possibility of a one-year award where the research plan justified it. An applicant could request a multi-year period and receive a shorter one, but not a longer period than requested. Established groups were the main intended applicants. The official guidance also allowed consideration of a newly established group where its leader had completed a successful postdoctoral period and the research plan was particularly robust. There was not one fixed amount for every research grant in the call, so applicants built a budget for the proposed work rather than relying on a single published award figure.
The dissertation grants were €4,000 each and were available once per person. They were aimed at researchers whose dissertation work was already in its final stages. Applicants needed relevant published articles or other evidence that the work was advanced. A grant was not awarded if the applicant’s dissertation had been approved before the application deadline elapsed. This was a completion incentive for eligible doctoral researchers, not an early-stage doctoral stipend.
Who could apply and what the restrictions meant
The funded research had to take place in Finland. The call did not describe applicant nationality as the central eligibility test; it focused on where the research would be conducted, the applicant’s suitability for the grant category and the project’s cancer relevance. Major and research grants were intended for senior-level researchers. A newly established group was a possible exception for research grants under the conditions described above, rather than a general waiver of the experience and proposal-quality expectations.
The foundation would consider only one application per applicant in the call. A researcher could have only one Cancer Foundation Finland grant at a time. These rules made grant-category choice consequential. The major grant was for a large, multi-year research programme; the research-grant route supported other investigator-led work; and the dissertation grant had a distinct late-stage doctoral purpose. The major-grant page noted that an application not nominated for a major award could be considered among the other research grants, but that should not be mistaken for permission to file multiple applications.
Company research and product-development projects were excluded. The research-grant guidance also set a tobacco-industry funding restriction for researchers and teams funded by the tobacco industry. Its detailed description covers companies or groups of companies deriving a major portion of income from manufacturing or marketing tobacco or other nicotine products. Researchers needed to check their funding circumstances against the foundation’s full wording rather than infer an exemption from the project’s scientific subject.
The assessment criteria were substantive, not just administrative. Reviewers considered the quality and feasibility of the research plan, the applicant’s scientific merits and the project’s relevance to cancer. The plan needed a defined purpose and objective; the foundation expressly cautioned that a general description of a research area was not a research plan. For applicants, this meant explaining what the project would do, how its work could be completed, and why its contribution belonged within cancer research.
How applications were submitted in the closed round
Applications were made in English through Cancer Foundation Finland’s electronic grant application system. The call pages link directly to the system. The detailed call text and linked category guidance gave the application period as 1 June through 19 August 2026, while the call page’s headline summary says 1 July through 19 August. The category pages confirm that the system closed on 19 August 2026 at 23:59. Applications could not be supplemented after that point; late applications and applications that did not comply with the instructions would be rejected. This archive preserves the confirmed closing time and notes the discrepancy in the published opening date; these are records of how the closed call worked, not steps for applying now.
The research plan and supporting documents differed by grant category. For a major grant or a research grant, the research plan could be no more than five pages including references, and its type had to be at least 12 point. The foundation’s suggested structure covered background, objective, implementation and methods, schedule, division of work in the team, the cost estimate, ethical considerations and impact. The principal researcher supplied a publication list covering publications from 2016–2026. Only five key publications were entered on the application form, with a fuller list appended. A publication could be included as in press if it had been approved for publication; a submitted manuscript did not yet qualify. An application for a clinical interventional study or trial needed its study protocol, or a synopsis if the protocol was not available.
For dissertation grants, the plan limit was three pages including references, also using at least 12 point type. Applicants supplied a list of their publications, with publications included in the dissertation entered on the form and a fuller list appended. The foundation’s dissertation guidance likewise treated an in-press publication as eligible only after it had been approved for publication; submission alone was insufficient. The applicant’s work had to be sufficiently advanced, and relevant publications or other evidence of that progress supported the case.
The foundation requested a popular Finnish-language summary for major and research grants. It was public-facing and was not to contain confidential project information. It was expected to explain the rationale and aim, methods, expected results and benefits, including possible societal contributions to cancer prevention, diagnosis, treatment and support for patients. The instructions allowed the summary to be in English if the principal researcher’s native language was not Finnish. This summary was part of explaining the value of the proposed work, rather than a substitute for the technical research plan.
Applicants for research grants and major grants also needed to present the research team’s involvement and time commitment in the form. The principal investigator’s CV was the CV to append, while the plan was expected to explain team members’ relevant expertise. Assisting staff were not counted as research-team members under the instructions. Budget planning had to include the project’s actual costs. Recipients of major and research grants did not receive separate travel grants for the same call, so research and conference travel had to be budgeted within the application. The published overhead reimbursement ceiling was 15 percent of the grant.
Review, decisions and payment after the deadline
The official guidance says the Grants Committee proposes awards and the foundation’s Board makes the decisions. The call page places the announcement of the 2026 awards in December 2026. Its broader description of the grants process says summer research and dissertation applications are reviewed by expert committees and that assessments consider applicant merits, the quality of the plan and the project’s cancer relevance. Applicants therefore had to allow for review after the summer submission window rather than expect a decision at the closing date.
For successful applicants, payment arrangements followed the award decision. The research and major grants were paid to the account of the research site in instalments every six months; the first instalment was set for January 2027. Dissertation grants were to be paid to the applicant’s account in January 2027. The recipient supplied payment details through the grant application system. The research guidance set a maximum of 15 percent of a research grant for overheads paid to the research site. These payment details are useful to understand the 2026 award structure but do not create a new opportunity for applicants.
Recipients also took on reporting and accounting responsibilities for research funding. The foundation required grantees to report results and account for the use of funds. For a dissertation grant, the foundation described a more limited reporting step: after the dissertation was approved and published, the recipient sent a permanent link using the reporting form, and no accounts statement was required for that personal grant. Applicants with prior Cancer Foundation Finland awards needed to have reported and accounted for those grants as required; compliance was a condition for payment of a new award.
Practical record for future applicants
Although this round has closed, its published structure can help prospective applicants understand the foundation’s expectations. A research group considering a later call can prepare a clearly defined cancer-research question, a feasible plan, an appropriate budget and an explanation of the Finnish research setting. It can also identify which grant category fits the scale and career stage of the work. A senior investigator building a larger programme might track the major-grant criteria, while a smaller or shorter project may fit the research-grant route. A doctoral researcher should compare their stage of work with the foundation’s final-stage dissertation requirement.
Preparation should begin with the research purpose and feasibility, not simply with the size of the available award. The foundation asks how the proposed work relates to cancer and whether the researcher can carry it out. A persuasive plan makes its objective legible, sets out the methods and schedule, addresses ethics and cost, and states what outcomes may matter for cancer prevention, diagnosis, treatment or patient support. A plan that names a disease area without explaining the project’s direct relevance would not satisfy the stated requirement by itself.
For a future application, do not reuse the 2026 dates, award amounts or attachment instructions without checking the next official call. The foundation says its annual research and dissertation grant dates are announced on its website, and its call page is the controlling place to confirm whether applications are open. Category pages contain details that may change from one round to another. An applicant should use the call year’s current forms and rules, particularly for eligibility, research-plan length, publication-list period, funding amount, timetable and electronic submission.
This archive records the 2026 programme only. It does not claim that a future round has opened or that its terms will remain the same. Until the foundation posts a new announcement, the 2026 deadline remains the relevant historical closing date and the page should be read as background on a completed competition.